Literature DB >> 10091273

Exercise metabolism and beta-blocker therapy. An update.

A Head1.   

Abstract

The rationale for the concurrent prescription of beta-blockers and programmes of exercise is that both medication and physical activity can improve the quality of life of patients with cardiovascular disease. Difficulties arise when drugs reduce either the physical ability or the motivation to exercise. This article focuses on the physiological limitations to prolonged aerobic exercise in patients receiving beta-blockers. Possible limiting factors to exercise while taking beta-blockers include reduction in heart rate and cardiac output, local alterations to blood flow, changes to muscle and liver glycogenolysis, and alterations to adipose and intra-muscular lipolysis. The disadvantages and advantages of nonselective and beta 1-selective drugs are discussed, as well as those of drugs that have beta 2-agonist properties. Particular emphasis is placed upon the beta-blocker-induced attenuation of the normal increase in fat oxidation during prolonged exercise. There are physiological advantages, especially for the physically active individual, in prescribing beta 1-selective rather than nonselective drugs in controlled release, rather than conventional release, form. Additionally, there may be further advantages in prescribing drugs which have partial agonist properties at beta 2 receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10091273     DOI: 10.2165/00007256-199927020-00002

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  117 in total

1.  Exercise Testing, Training, and Beta-Adrenergic Blockade.

Authors:  J H Wilmore
Journal:  Phys Sportsmed       Date:  1988-12       Impact factor: 2.241

2.  Can the biochemical responses to a beta 2-adrenoceptor stimulant be used to assess the selectivity of beta-adrenoceptor blockers?

Authors:  S Rolf Smith; M J Kendall; D J Worthington; R Holder
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

3.  Effect of dual beta-blockade and calcium antagonism on endurance performance.

Authors:  N F Gordon; J P van Rensburg; D P van den Heever; N B Kalliatakis; D P Myburgh
Journal:  Med Sci Sports Exerc       Date:  1987-02       Impact factor: 5.411

4.  Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men.

Authors:  L Gullestad; K Birkeland; G Nordby; S Larsen; J Kjekshus
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

5.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

6.  Effect of beta-receptor blockade on splanchnic and muscle metabolism during prolonged exercise in men.

Authors:  G Ahlborg; A Juhlin-Dannfelt
Journal:  J Appl Physiol (1985)       Date:  1994-03

7.  Effect of beta 1-selective and nonselective beta blockade on blood pressure relative to physical performance in men with systemic hypertension.

Authors:  P Kaiser; B Hylander; K Eliasson; L Kaijser
Journal:  Am J Cardiol       Date:  1985-04-26       Impact factor: 2.778

8.  Effects of beta 1-selective and nonselective beta-adrenoceptor blockade during exercise conditioning in healthy adults.

Authors:  A A McLeod; W E Kraus; R S Williams
Journal:  Am J Cardiol       Date:  1984-06-01       Impact factor: 2.778

9.  K+ balance of the quadriceps muscle during dynamic exercise with and without beta-adrenoceptor blockade.

Authors:  L Gullestad; J Hallén; O M Sejersted
Journal:  J Appl Physiol (1985)       Date:  1995-02

Review 10.  Carvedilol in ischaemic heart disease.

Authors:  B N Prichard
Journal:  Cardiology       Date:  1993       Impact factor: 1.869

View more
  3 in total

Review 1.  The rush to adrenaline: drugs in sport acting on the beta-adrenergic system.

Authors:  E Davis; R Loiacono; R J Summers
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

2.  Proof of concept of a 45-second cardiorespiratory fitness self-test for coronary artery disease patients based on accelerometry.

Authors:  Gabriele Papini; Alberto G Bonomi; Wim Stut; Jos J Kraal; Hareld M C Kemps; Francesco Sartor
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

3.  Effects of surgical and FFP2 masks on cardiopulmonary exercise capacity in patients with heart failure.

Authors:  Alexander Kogel; Pierre Hepp; Tina Stegmann; Adrienn Tünnemann-Tarr; Roberto Falz; Patrick Fischer; Felix Mahfoud; Ulrich Laufs; Sven Fikenzer
Journal:  PLoS One       Date:  2022-08-23       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.